The prescription of medicinal cannabis in Australia has skyrocketed, with over half of all approvals targeting non-cancer chronic pain. However, a deep dive into clinical trial data and guidelines from the Therapeutic Goods Administration (TGA) reveals a stark contrast between patient anecdotes and scientific evidence. Researchers warn that the modest benefits of cannabinoids must be carefully weighed against the rising risks of cannabis use disorder and severe pharmacological interactions.
The Surge in Approvals vs. Clinical Reality
Since regulatory barriers were lowered in 2016, Australia’s health regulator has issued more than 700,000 approvals for medicinal cannabis products, which include oils, capsules, dried flowers, and gummies containing active cannabinoids like THC and CBD. Approximately 50% of these approvals are intended to treat chronic non-cancer pain, a condition that affects one in five Australians over 45.
Despite this massive uptake, the clinical evidence remains underwhelming. A comprehensive 2021 review of 32 randomised controlled trials involving nearly 5,200 patients found only "small improvements" in pain, physical functioning, and sleep when compared to a placebo. A previous systematic review highlighted a sobering statistic: to achieve a mere 30% reduction in pain for just one person, 24 people would need to be treated with medicinal cannabis.
Consequently, the Faculty of Pain Medicine has officially recommended that the use of medical cannabis for pain management should be strictly limited to clinical trials.
TGA Guidelines: A Treatment of Last Resort
Australia’s Therapeutic Goods Administration (TGA) reflects this clinical skepticism. The TGA explicitly states that there is "limited evidence" that medicinal cannabis provides clinically significant relief for most pain conditions. Therefore, the regulator advises that cannabinoids should only be trialed when all other standard, evidence-based therapies have failed.
Furthermore, the TGA warns against inhaled cannabis products, recommending pharmaceutical-grade extracts (such as nabiximols) as a safer alternative to raw flower vaporization.
The Hidden Risks: Interactions and Addiction
While patient anecdotes often praise the drug, clinical research shows that more people experience side effects than report actual benefits. These adverse effects—including sedation, dizziness, and cognitive slowing—are exacerbated by the increasing prevalence of high-potency THC products, which accounted for more than half of all approvals in 2025.
The pharmacological risks are severe. Medical cannabis can dangerously interact with other medications, particularly opioids, anti-epileptics, blood thinners, and immunosuppressants. Even CBD, widely marketed as non-intoxicating, has been linked to serious drug interactions. This risk is heavily compounded by the rise of standalone "telehealth clinics," which often prescribe cannabis without consulting the patient's primary care physician, leading to fragmented and dangerous patient care.
Perhaps most alarming is the risk of dependency. A 2024 study revealed that one in four people using medical cannabis eventually develop a cannabis use disorder. Long-term use builds tolerance, requiring higher doses that trigger withdrawal symptoms such as irritability and severe cravings.
Expert Verdict: Weighing the Alternatives
The surge in medicinal cannabis prescriptions highlights a systemic failure in providing accessible, effective chronic pain care in Australia, especially outside major cities. While cannabis may offer relief for a small subset of treatment-resistant patients, it is not a silver bullet. Evidence-based interventions like cognitive behavioral therapy (CBT) and physical exercise remain the gold standard with significantly fewer risks. Patients considering cannabinoids must consult their primary healthcare provider to ensure the modest potential benefits do not trigger severe pharmacological or psychological harm.
